Recursion Pharmaceuticals (RXRX) EBT Growth (3y) (2023 - 2026)

Recursion Pharmaceuticals (RXRX) EBT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -23.18%

Historic Data

Download Data
DateValue
Mar 31, 2026 -23.18%
Dec 31, 2025 -18.76%
Sep 30, 2025 -37.37%
Jun 30, 2025 -37.44%
Mar 31, 2025 -53.53%
Dec 31, 2024 -40.16%
Sep 30, 2024 -27.08%
Jun 30, 2024 -31.19%
Mar 31, 2024 -44.19%
Dec 31, 2023 -55.63%
Sep 30, 2023 -59.61%
Jun 30, 2023 -60.25%
Mar 31, 2023 -51.87%